瑞格列奈治疗初发2型糖尿病患者  

The clinical observations of repaglinide in newly diagnosed type 2 diabetic patients

作　　者：胡茂清[1] 罗玉[1] 张伟[1] 杨雪[1] 张林[1] 

机构地区：[1]成都中医药大学第三附属医院四川省糖尿病防治中心,四川成都610041

出　　处：《四川医学》2009年第6期837-838,共2页Sichuan Medical Journal

摘　　要：目的了解瑞格列奈对初发2型糖尿病患者的血糖控制的有效性和安全性。方法通过对11例初发2型糖尿病患者用瑞格列奈治疗16周的观察。在治疗0周,治疗16周分别测体重,BMI,腰臀比,OGTT实验以及糖化血红蛋白(HbAlc)水平,了解治疗16周中的低血糖发生情况。结果治疗前后11例患者的体重,BMI及腰臀比无明显变化(P>0.05),治疗16周后OGTT的0、30、60、120min血浆葡萄糖水平以及糖化血红蛋白水平均较治疗前明显降低,差异有统计学意义(P<0.05)。治疗期间仅1例发生轻微低血糖。结论诺和龙对2型糖尿病患者在不增加体重和BMI的同时,安全有效降低血糖和糖化血红蛋白水平,是初发2型糖尿病患者治疗糖尿病的首选方案之一。Objective To investigate the efl3cacy and satefy of repaglinide to treat newly diagnosed type 2 diabetic patients. Methods 11 subjects newly diagnosed type 2 diabetes were treated with repaglinide for 16wecks. Weight, BMI, hip and waist circumference ratio,oral glucos tolerant test and HbAlc were measured at 0 week and 16 week respectively. Hypoglycemia was also observed. Results No significant differences in weight, BMI, hip and waist circumference ratio observed at 0 week and 16 week. The levels of plasma glucose of OGTT at zero 0 ,30 ,60 , 120 minute and HbAlc were significant lower at 16 week compared with 0 week （P〈0.05）. There was only one case who had mild hypoglycemia in the 16 weeks. Conclusion Repaglinide is an effective and safe treatment way for type 2 diabetes mellitus while the weight and BMI do not change much. Repaglinide can be used for one of the first choices for treating newly diagnosed type 2 diabetic patients.

关 键 词：初发2型糖尿病 诺和龙 血糖控制 安全性 

分 类 号：R587.1[医药卫生—内分泌]